Biogen Inc. investors can advance their claim that the company misrepresented clinical trial data for its Alzheimer’s drug, a federal judge ruled.

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

Focus remains on Alzheimer's and rare disease markets. Biogen demonstrated solid performance ... to prevent any background ...

Biogen has four other Alzheimer's candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned. The decision ...

After the speakers’ remarks ... the impact that -- that could have on Alzheimer's. So Alzheimer's is going to be a core franchise for Biogen for decades to come. You know, we had very positive ...

Eisai Co. Ltd. and Biogen Inc. on Tuesday said their experimental Alzheimer’s drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the ...

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's ...

Biogen has also won full approval with its Japanese business partner Eisai for another closely watched Alzheimer’s drug called Leqembi. That drug requires intravenous infusions every other week ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...